Kadans’ London Innovation Centre at Canary Wharf, London has launched its wet lab innovation and flexible workspace centre and welcomed a new tenant.
AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre.
The Innovation Centre has enabled the rapid growth of the life sciences hub at Canary Wharf, providing opportunities for early-stage life science companies to collaborate and innovate.
AviadoBio joins a host of life sciences and healthcare organisations already based at Canary Wharf, including government-owned genomic health pioneer, Genomics England, Barts Health NHS Trust, the Medicines and Healthcare products Regulatory Agency, the Medical Defence Union, the General Pharmaceutical Council and NHS Transformation.
Kadans and Canary Wharf Group are also progressing their joint venture to develop an GIA commercial health and life sciences building, the largest in Europe, on the 3.3-hectare North Quay site, which is expected to be complete in 2027.
Lisa Deschamps, CEO of AviadoBio, said that the new space “allows us to more comfortably accommodate our growing team who is focused on developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)”, adding: “The accessibility to others in the life science space further supports our company’s culture and focus on nurturing breakthrough discoveries.”
Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World
Image shows: Canary Wharf, London, UK.
